Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases

• Published in: Clinical & translational oncology 2015-11, Vol.17 (11), p.870-875
• Main Authors: Qiang, W.-G., Shi, L.-R., Li, X.-D., Wu, Q.-Q., Zhao, J.-M., Chen, L.-J., Yang, Y., Wu, J., Ji, M., Wu, C.-P.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - secondary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms - drug therapy; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Research Article; Retrospective Studies; Salvage Therapy - methods
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-015-1317-8

Backgrounds The present study aimed to evaluate benefit of hepatic arterial infusion chemotherapy (HAI) combined with systemic chemotherapy (SCT) for patients with colorectal liver metastases (CLMs) in a palliative setting. Methods This was a retrospective single-center study including 43 consecutive patients with CLM after failure of standard SCT. Among them, 20 (47 %) patients underwent HAI combined with SCT (Group A) and 23 historical control patients who had received SCT with or without targeted agent treatment (Group B). Results The two groups had similar characteristics. Compared with SCT alone, HAI combined with SCT prolonged survival (median 19.8 vs. 9.0 months; P  = 0.045). Median hepatic progression-free survival was significantly longer for HAI combined with SCT vs. SCT alone (median 8.1 vs. 4.7 months; P  = 0.027), as were response rates (25 and 0 %; P  = 0.038) and progression-free survival (median 5.7 vs. 3.0 months; P  = 0.02). Three patients (15 %) achieved conversion to potentially curative surgery. Grade 3/4 toxicities for Group A and Group B were neutropenia (5 and 8.7 %, respectively), anemia (5 and 0 %, respectively), and hyperbilirubinemia (0 and 4.3 %, respectively). Other complications were mostly grade 1 or 2. Conclusions HAI combined with SCT treatment can improve overall survival compared with SCT alone in highly advanced CLM refractory to intravenous chemotherapy.